 |
|
Cumulative Glycemic Exposure and Microvascular Complications in Insulin-Dependent Diabetes MellitusThe Glycemic Threshold Revisited
Trevor J. Orchard, MBBCh, MMSc;
Kimberly Y.-Z. Forrest, PhD;
Demetrius Ellis, MD;
Dorothy J. Becker, MBBCh
Arch Intern Med. 1997;157(16):1851-1856.
Abstract
| |
Background
The development of microvascular insulindependent diabetes mellitus (IDDM) complications has been shown to be related to both duration of diabetes and the degree of glycemic exposure. However, controversy exists as to whether there is a threshold of glycemic exposure, below which there is minimal risk. Furthermore, there are few data describing the relationship of total glycemic exposure (duration x degree) to complications rates—a potentially useful research and clinical tool.
Objectives
To determine a cumulative glycemic exposure variable that combines the effect of both degree and duration of hyperglycemia and to evaluate this variable in terms of its relation to microvascular complications. The association between cumulative glycemic exposure and complication risk was also examined to evaluate whether there was a threshold effect.
Methods
A total of 353 patients with IDDM who had completed the first 6 years of follow-up in the Pittsburgh Epidemiology of Diabetes Complications Study were included in this analysis. These subjects had a mean age of 27.9 years, and the mean duration of the disease was 19.4 years. Subjects were examined at baseline (cycle 1) and then biennially (cycle 2, cycle 3, and cycle 4) for diabetes complications. Total glycosylated hemoglobin (HbA1) was measured at each cycle. A cumulative glycemic exposure variable, named A1months, was calculated by multiplying the number of HbA1 units above normal at each cycle by the number of months between the midpoints of the preceding and succeeding cycle intervals.
Results
The mean number of A1months experienced at the time of diagnosis of proliferative retinopathy (914), microalbuminuria (952), overt nephropathy (1043), and distal symmetrical polyneuropathy (1043) did not vary by duration of diabetes. Thus, approximately 1000 A1months were needed (on average) for the advanced complications to develop. Although the risk for developing proliferative retinopathy rose gradually as A1months increased, a more abrupt increase in the risk was seen (again at approximately 1000 A1months) for microalbuminuria (odds ratio, 6.9; 95% confidence interval, 2.5-19.1), overt nephropathy (odds ratio, 6.5; 95% confidence interval, 2.0-21.7), and distal symmetrical polyneuropathy (odds ratio, 6.5; 95% confidence interval, 2.4-17.8). Nonetheless, complications developed in the majority of cases at glycemic exposures below 1000 A1months. The cumulative glycemic exposure variable A1months does not predict complications any better than its component variables (duration and HbA1). Furthermore, formal statistical testing failed to show a definitive threshold for any complication.
Conclusions
Although A1months does not enhance prediction of complications, it may be a useful summary measure of glycemic exposure for both patients and physicians. However, although subjects with 1000 A1months or more appear to be at increased risk of developing most microvascular complications, because the majority of complications arise in subjects with less than this exposure, this threshold value should only be considered a minimal goal. For example, our data suggest that for most microvascular complications to develop, it would take, on average, 83 years with an HbA1 unit at 1% above normal, 42 years at 2% above normal, 28 years at 3% above normal, 21 years at 4% above normal, and 18 years at 5% above normal.
Arch Intern Med. 1997;157:1851-1856
Author Affiliations
From the Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh (Drs Orchard and Forrest), and the Division of Nephrology and Endocrinology, Children's Hospital of Pittsburgh (Drs Ellis and Becker), Pittsburgh, Pa.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Intraretinal Leakage and Oxidation of LDL in Diabetic Retinopathy
Wu et al.
IOVS 2008;49:2679-2685.
ABSTRACT
| FULL TEXT
Modeling Chronic Glycemic Exposure Variables as Correlates and Predictors of Microvascular Complications of Diabetes: Response to Dyck et al.
Orchard et al.
Diabetes Care 2007;30:448-448.
FULL TEXT
Modeling Chronic Glycemic Exposure Variables as Correlates and Predictors of Microvascular Complications of Diabetes: Response to Orchard et al.
Dyck et al.
Diabetes Care 2007;30:448-449.
FULL TEXT
Modeling Chronic Glycemic Exposure Variables as Correlates and Predictors of Microvascular Complications of Diabetes
Dyck et al.
Diabetes Care 2006;29:2282-2288.
ABSTRACT
| FULL TEXT
Cognitive Ability and Brain Structure in Type 1 Diabetes: Relation to Microangiopathy and Preceding Severe Hypoglycemia
Ferguson et al.
Diabetes 2003;52:149-156.
ABSTRACT
| FULL TEXT
Psychological Impact of Changing the Scale of Reported HbA1c Results Affects Metabolic Control
Hanas
Diabetes Care 2002;25:2110-2111.
FULL TEXT
Effect of Intensive Therapy on the Microvascular Complications of Type 1 Diabetes Mellitus
The Writing Team for the Diabetes Control and Comp
JAMA 2002;287:2563-2569.
ABSTRACT
| FULL TEXT
A Nonlinear Effect of Hyperglycemia and Current Cigarette Smoking Are Major Determinants of the Onset of Microalbuminuria in Type 1 Diabetes
Scott et al.
Diabetes 2001;50:2842-2849.
ABSTRACT
| FULL TEXT
Lipid and Blood Pressure Treatment Goals for Type 1 Diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study
Orchard et al.
Diabetes Care 2001;24:1053-1059.
ABSTRACT
| FULL TEXT
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
Stratton et al.
BMJ 2000;321:405-412.
ABSTRACT
| FULL TEXT
Diabetes: a time for excitement---and concern
Orchard
BMJ 1998;317:691-692.
FULL TEXT
Is There a Glycemic Threshold?
Haffner
Arch Intern Med 1997;157:1791-1791.
ABSTRACT
|
